To evaluate safety and efficacy of tedizolid phosphate in the management of several skin infections
DOI:
Abstract
Tedizolid Phosphate is an oxazolidinone-class antibiotic and is used for the treatment of acute bacterial skin and skin structure infections. it is a prodrug activated by plasma or intestinal phosphatases to tedizolid following administration of the drug either orally or intravenously. Once activated, tedizolid exerts its bacteriostatic microbial activity through inhibition of protein synthesis by binding to the 50S ribosomal subunit of the bacteria. The purpose of the study was to evaluate safety and efficacy of Tedizolid phosphate and compare it with that of Lenizolid Phosphate another oxazolidinone class of drugs. The study was conducted at OMNI hospital located at dilsukhnagar, Hyderabad. 126 subjects with skin infections, who satisfied the eligibility criteria, were accrued during the study period. These patients were randomized into 2 groups, and were then evaluated according to the treatment protocol. Investigational product was then administered to evaluate safety and efficacy parameters. Subjects received treatment according to the study arm/group. Subjects were asked to take drug for 7 days daily once orally till the clinical symptoms disappear/ as per PIs discretion. Samples for microbiological evaluation were done at screening, end of the therapy. Among both the formulations the group the received Tedizolid phosphate was considered safer and more efficacious as Clinical success rate was 89.9% and the group that received Lenizolid phosphate had the clinical success rate of 81%. It can be concluded that Tedizolid phosphate could be promising drug in the treatment of various skin infections.
Downloads
Copyright (c) 2019 Rubatosis Publications
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The author(s) acknowledged that the manuscript submitted is his/her/their own original work; all Authors participated in the work in a substantive way and are prepared to take public responsibility for the work; all authors have seen and approved the manuscript as submitted; the manuscript has not been published and is not being submitted or considered for publication elsewhere; the text, illustrations, and any other materials included in the manuscript do not infringe (plagiarism) upon any existing copyright or other rights of anyone. Not with standing the above, the Contributor(s) or, if applicable the Contributor’s Employer, retain(s) all proprietary rights other than copyright, such as Patent rights; to use, free of charge, all parts of this article for the author’s future works in books, lectures, classroom teaching or oral presentations; the right to reproduce the article for their own purposes provided the copies are not offered for sale. All persons who have made substantial contributions to the work reported in the manuscript, bu t who are not contributors, are named in the Acknowledgment and have given me/us their written permission to be named. If I/we do not include an Acknowledgment that means I/we have not received substantial contributions from non -contributors and no contributor has been omitted. Further, I/We agreed to take all the public responsibility with regard to the views expressed in the Article.
We Locate at
:+91-9703529294.
